Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators declaring it safe

Donanemab: Everything we know about the latest Alzheimer’s drug rejected by the NHS - Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in researc

A retired journalist who took part in the clinical trial for the new Alzheimer’s drug has described how he feels “as normal as a 78-year-old can be” but fears what happens now he has to stop taking it. Peter Almond finished a trial for Donanemab in September having been on the drug for three years.